Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: The present disclosure relates to ocular mucoadhesive pharmaceutical compositions comprising fluoroquinolone antibiotic, chitosan, polyvinyl alcohol and polyvinylpyrrolidone, their uses and methods of using such compositions.

Abstract: Subject matter of the present invention is a white crystalline polymorph A of the Ca salt of a compound according to formula I or a solvate and/or a hydrate thereof with a molar ratio of a compound according to formula I or a solvate and/or a hydrate thereof to calcium which is 2±0.3. Subject matter of the present invention is in particular a compound according to formula I or a solvate and/or a hydrate thereof which is characterized by an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2theta at ±0.2 of the values shown below: 2 theta=5.91°, 9.64°, 16.78°, 17.81°, 19.81°, 25.

Abstract: A process for preparing a sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1?,2?:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate of Formula 1 and its polymorphic form thereof.

Abstract: Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of at least one of R1-R18, (e.g., R3, R7 and R12) is linked to the steroidal backbone by a urethane group: At least one of R1-R18, (e.g., R3, R7 and R12) has the following urethanyl structure: —O—(C?O)—NR19R20 where R19 and R20 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aminoalkyl, aminoalkenyl, aminoalkynyl, or aminoaryl, provided that at least one of R19 or R20 includes an amino group (e.g., R19 is hydrogen and R20 is (C2-C6)aminoalkyl). R18 can have the following structure: —R21—(C?O)—NR22R23 where R21 is omitted or alkyl, alkenyl, alkynyl, or aryl, and R22 and R23 are hydrogen, alkyl, alkenyl, alkynyl, or aryl, provided that at least one of R22 or R23 is not hydrogen.

Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

Abstract: The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib:oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 olaparib oxalic acid cocrystal, and a 2:1 olaparib oxalic acid cocrystal. The invention also relates to pharmaceutical compositions containing an olaparib oxalic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib oxalic acid cocrystals of the invention Got may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP). These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure).

Abstract: The disclosure relates thieno[2,3-d]pyrimidin-4-one derivatives as modulators of NMDA receptors and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing conditions related to cognition, typically prevention or treatment of neurological conditions related to the NMDA receptor.

Abstract: Synthesis of a compound N-[(4,6-dimethylpyrimidin-2-yl)carbamothioyl]pyridine-3-carboxamide and its use as an insecticidal agent.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.

Abstract: The present invention relates to novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.

Abstract: Provided herein are novel ready-to-use bortezomib formulations, methods of preparing, and methods of using the same.

Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

Abstract: The invention concerns the use, as a pharmaceutical or cosmetic excipient, of a composition which is solid at ambient temperature and in the form of individualized particles, said composition comprising: lauroyl macrogolglyceride, polyethylene glycol.

Abstract: A N?-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide compound, its synthesis, and its use as an anti-microbial agent.

Abstract: Synthesis of a compound 1,3-bis(naphthalen-1-yloxy)propan-2-one and its use as an insecticidal agent.

Abstract: A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.

Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.